{ "meta": { "total_records": 78, "timestamp": "2026-06-02T18:33:29Z" }, "data": [ { "category": "Human", "medicine_affected": "Champix", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "varenicline", "therapeutic_area_mesh": "Tobacco Use Cessation", "pharmaceutical_forms_affected": "Film-coated tablet", "strengths_affected": "0.5 mg;1 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "June 2025", "first_published_date": "08/07/2021", "last_updated_date": "28/05/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/champix" }, { "category": "Human", "medicine_affected": "NovoNordisk insulin (human insulin) (various short-, rapid-, intermediate-, mixed- and long-acting forms)", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "Solution for injection;Suspension for injection", "strengths_affected": "100 units/ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "31/10/2025", "last_updated_date": "27/05/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/novonordisk-insulin-human-insulin-various-short-rapid-intermediate-mixed-long-acting-forms" }, { "category": "Human", "medicine_affected": "NexoBrid", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "concentrate of proteolytic enzymes enriched in bromelain", "therapeutic_area_mesh": "Debridement", "pharmaceutical_forms_affected": "", "strengths_affected": "", "availability_of_alternatives": "No", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "06/05/2026", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/nexobrid" }, { "category": "Human", "medicine_affected": "Quetiapine", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "", "therapeutic_area_mesh": "Schizophrenia;Bipolar Disorder;Depressive Disorder", "pharmaceutical_forms_affected": "Extended-release tablet", "strengths_affected": "50 mg;150 mg;200 mg;300 mg;400 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "11/03/2025", "expected_resolution_date": "", "expected_resolution": "Within the second quarter of 2027", "first_published_date": "11/03/2025", "last_updated_date": "04/05/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/quetiapine" }, { "category": "Human", "medicine_affected": "Methotrexate", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "methotrexate", "therapeutic_area_mesh": "Cancer;Neoplasms;Arthritis, Rheumatoid;Arthritis;Psoriasis;Crohn Disease", "pharmaceutical_forms_affected": "Solution for injection", "strengths_affected": "Various", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "09/08/2023", "last_updated_date": "24/04/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/methotrexate" }, { "category": "Human", "medicine_affected": "Hycamtin", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "topotecan", "therapeutic_area_mesh": "Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma", "pharmaceutical_forms_affected": "Capsule, hard", "strengths_affected": "0.5 mg;1 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "07/11/2023", "last_updated_date": "24/04/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/hycamtin" }, { "category": "Human", "medicine_affected": "Menopur", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "menotropin", "therapeutic_area_mesh": "Infertility", "pharmaceutical_forms_affected": "Powder and solvent for solution for injection", "strengths_affected": "1200 IU", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "End of 2025", "first_published_date": "05/04/2023", "last_updated_date": "24/04/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/menopur" }, { "category": "Human", "medicine_affected": "Perfusion solutions", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "", "therapeutic_area_mesh": "Perfusion;Infusions, Intravenous;Therapeutic Irrigation", "pharmaceutical_forms_affected": "Intravenous use;Solution for infusion;Irrigation solution", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "End of 2025", "first_published_date": "12/06/2025", "last_updated_date": "24/04/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/perfusion-solutions" }, { "category": "Human", "medicine_affected": "Moventig", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "", "strengths_affected": "12.5 mg;25 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "18/08/2025", "last_updated_date": "21/04/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/moventig" }, { "category": "Human", "medicine_affected": "Creon", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "pancreas powder;pancrelipase", "therapeutic_area_mesh": "Pancreatic Diseases", "pharmaceutical_forms_affected": "Capsule", "strengths_affected": "10,000 units;25,000 units;35,000 units", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "First half of 2027", "first_published_date": "29/04/2024", "last_updated_date": "14/04/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/creon" }, { "category": "Human", "medicine_affected": "Eli Lilly insulin (various forms)", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "Solution for injection;Suspension for injection", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "23/03/2026", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/eli-lilly-insulin-various-forms" }, { "category": "Human", "medicine_affected": "Ifosfamide", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "ifosfamide", "therapeutic_area_mesh": "Cancer", "pharmaceutical_forms_affected": "Powder for concentrate for solution for infusion", "strengths_affected": "", "availability_of_alternatives": "Unknown", "start_of_shortage_date": "12/02/2026", "expected_resolution_date": "", "expected_resolution": "Expected to continue until Q1 2027.", "first_published_date": "13/02/2026", "last_updated_date": "03/03/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/ifosfamide" }, { "category": "Human", "medicine_affected": "Cyclophosphamide", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "cyclophosphamide", "therapeutic_area_mesh": "Cancer", "pharmaceutical_forms_affected": "Powder for solution for injection or infusion", "strengths_affected": "", "availability_of_alternatives": "Unknown", "start_of_shortage_date": "24/02/2026", "expected_resolution_date": "", "expected_resolution": "Expected to continue until Q1 2027.", "first_published_date": "24/02/2026", "last_updated_date": "03/03/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cyclophosphamide" }, { "category": "Human", "medicine_affected": "Natpar", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "parathyroid hormone", "therapeutic_area_mesh": "Hypoparathyroidism", "pharmaceutical_forms_affected": "Powder and solvent for solution for injection", "strengths_affected": "100 micrograms/dose ;75 micrograms/dose ;50 micrograms/dose ;25 micrograms/dose", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "02/05/2022", "last_updated_date": "23/02/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/natpar" }, { "category": "Human", "medicine_affected": "Trulicity", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "dulaglutide", "therapeutic_area_mesh": "Diabetes Mellitus, Type 2", "pharmaceutical_forms_affected": "Solution for injection in pre-filled pen", "strengths_affected": "0.75 mg;1.5 mg;3 mg ;4.5 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "End of 2025", "first_published_date": "28/08/2023", "last_updated_date": "17/02/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/trulicity" }, { "category": "Human", "medicine_affected": "Norditropin FlexPro / Norditropin NordiFlex", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "somatropin", "therapeutic_area_mesh": "Dwarfism, Pituitary", "pharmaceutical_forms_affected": "Solution for injection in pre-filled pen", "strengths_affected": "5 mg ;10 mg ;15 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "Resolved - 22 December 2025", "first_published_date": "05/12/2023", "last_updated_date": "11/02/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/norditropin-flexpro-norditropin-nordiflex" }, { "category": "Human", "medicine_affected": "Tresiba", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "insulin degludec", "therapeutic_area_mesh": "Diabetes Mellitus", "pharmaceutical_forms_affected": "Pre-filled pen", "strengths_affected": "100 units/ml ;200 units/ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "24/08/2023", "last_updated_date": "09/02/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/tresiba" }, { "category": "Human", "medicine_affected": "Fludarabine", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "fludarabine", "therapeutic_area_mesh": "Leukemia", "pharmaceutical_forms_affected": "Concentrate for solution for injection/infusion", "strengths_affected": "25 mg/ml", "availability_of_alternatives": "Unknown", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "The shortage is expected to last until December 2025.", "first_published_date": "11/03/2024", "last_updated_date": "22/01/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fludarabine" }, { "category": "Human", "medicine_affected": "Ozempic", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "semaglutide", "therapeutic_area_mesh": "Diabetes Mellitus, Type 2", "pharmaceutical_forms_affected": "Pre-filled pen", "strengths_affected": "1 mg;0.5 mg;0.25 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "19/10/2022", "last_updated_date": "13/01/2026", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/ozempic" }, { "category": "Human", "medicine_affected": "Fiasp PumpCart (insulin aspart)", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "insulin aspart", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "Solution for injection in a cartridge", "strengths_affected": "100 units/mL", "availability_of_alternatives": "Yes", "start_of_shortage_date": "08/05/2025", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "12/05/2025", "last_updated_date": "18/12/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fiasp-pumpcart-insulin-aspart" }, { "category": "Human", "medicine_affected": "NovoRapid PumpCart (insulin aspart)", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "insulin aspart", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "Solution for injection in a cartridge", "strengths_affected": "100 units/mL", "availability_of_alternatives": "Yes", "start_of_shortage_date": "08/05/2025", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "12/05/2025", "last_updated_date": "18/12/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/novorapid-pumpcart-insulin-aspart" }, { "category": "Human", "medicine_affected": "Insulin lispro Sanofi", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "insulin lispro", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "Solution for injection in a cartridge;Solution for injection in pre-filled pen", "strengths_affected": "100 units/ml solution for injection in cartridges;100 units/ml solution for injection in pre-filled pen", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "The expected duration of the shortage is unknown.", "first_published_date": "08/12/2025", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insulin-lispro-sanofi" }, { "category": "Human", "medicine_affected": "Dynastat", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "parecoxib", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "Powder and solvent for solution for injection;Powder for solution for injection", "strengths_affected": "40 mg", "availability_of_alternatives": "Unknown", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "January 2026 in Malta; February 2026 in Greece; March 2026 in Cyprus and France; July 2026 in Bulgaria and Norway", "first_published_date": "14/04/2025", "last_updated_date": "04/12/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/dynastat" }, { "category": "Human", "medicine_affected": "ADHD medicines", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "atomoxetine;methylphenidate;lisdexamfetamine", "therapeutic_area_mesh": "Attention Deficit Disorder with Hyperactivity", "pharmaceutical_forms_affected": "Various presentations in various strengths", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "Depending on the medicine and the EEA country, the shortage may continue until the end of 2025.", "first_published_date": "18/12/2023", "last_updated_date": "20/11/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/adhd-medicines" }, { "category": "Human", "medicine_affected": "Risperidone", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "risperidone", "therapeutic_area_mesh": "Schizophrenia", "pharmaceutical_forms_affected": "Prolonged-release suspension for injection", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "Risperdal Consta - by the end of 2025; Risperidone Teva and Sperizak - to continue until the end of 2026 or beginning of 2027", "first_published_date": "19/11/2025", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/risperidone" }, { "category": "Human", "medicine_affected": "Bronchitol", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "mannitol", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "Inhalation powder", "strengths_affected": "40 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "14/11/2025", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/bronchitol" }, { "category": "Human", "medicine_affected": "Beriglobin", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "human normal immunoglobulin", "therapeutic_area_mesh": "Primary Immunodeficiency Diseases;Immunologic Deficiency Syndromes;Hepatitis A;Mucositis", "pharmaceutical_forms_affected": "Solution for injection in pre-filled syringe", "strengths_affected": "2 ml and 5 ml (160 mg/ml) solution", "availability_of_alternatives": "Depending on indication", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "11/11/2025", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/beriglobin" }, { "category": "Human", "medicine_affected": "Eldisine", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "vindesine", "therapeutic_area_mesh": "Leukemia, Promyelocytic, Acute", "pharmaceutical_forms_affected": "Solution for injection", "strengths_affected": "5 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "End of September 2025", "first_published_date": "23/02/2024", "last_updated_date": "03/11/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/eldisine" }, { "category": "Human", "medicine_affected": "Salbutamol inhalation products", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "salbutamol", "therapeutic_area_mesh": "Asthma;Pulmonary Disease, Chronic Obstructive", "pharmaceutical_forms_affected": "Inhaler;Nebuliser solution", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "05/06/2024", "last_updated_date": "31/10/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/salbutamol-inhalation-products" }, { "category": "Human", "medicine_affected": "Cyanokit", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "hydroxocobalamin", "therapeutic_area_mesh": "Poisoning", "pharmaceutical_forms_affected": "Powder for solution for infusion", "strengths_affected": "", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "19/12/2024", "last_updated_date": "30/10/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cyanokit" }, { "category": "Human", "medicine_affected": "Pazenir", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "paclitaxel", "therapeutic_area_mesh": "Breast Neoplasms", "pharmaceutical_forms_affected": "Powder for dispersion for infusion", "strengths_affected": "5 mg/ml", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "26/01/2023", "last_updated_date": "20/10/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/pazenir" }, { "category": "Human", "medicine_affected": "Fasturtec", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "rasburicase", "therapeutic_area_mesh": "Hyperuricemia", "pharmaceutical_forms_affected": "Powder and solvent for concentrate for solution for infusion", "strengths_affected": "7.5 mg / 5 ml", "availability_of_alternatives": "", "start_of_shortage_date": "31/03/2023", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "21/02/2023", "last_updated_date": "16/10/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fasturtec" }, { "category": "Human", "medicine_affected": "Ixiaro", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "Japanese encephalitis vaccine (inactivated, adsorbed)", "therapeutic_area_mesh": "Encephalitis, Japanese;Immunization", "pharmaceutical_forms_affected": "Suspension for injection", "strengths_affected": "6AU", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "25/05/2023", "last_updated_date": "16/10/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/ixiaro" }, { "category": "Human", "medicine_affected": "Emend", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "aprepitant", "therapeutic_area_mesh": "Vomiting;Postoperative Nausea and Vomiting;Cancer;Neoplasms", "pharmaceutical_forms_affected": "Powder for oral suspension", "strengths_affected": "80 mg;125 mg", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "12/04/2024", "last_updated_date": "14/10/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/emend" }, { "category": "Human", "medicine_affected": "Human normal immunoglobulins", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "human normal immunoglobulins", "therapeutic_area_mesh": "Primary Immunodeficiency Diseases;Immunologic Deficiency Syndromes", "pharmaceutical_forms_affected": "Solution for injection/infusion", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "To last until June 2026.", "first_published_date": "03/06/2024", "last_updated_date": "29/09/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/human-normal-immunoglobulins" }, { "category": "Human", "medicine_affected": "Ecalta", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "anidulafungin", "therapeutic_area_mesh": "Candidiasis", "pharmaceutical_forms_affected": "Powder for concentrate for solution for infusion", "strengths_affected": "100 mg", "availability_of_alternatives": "", "start_of_shortage_date": "01/07/2024", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "17/01/2025", "last_updated_date": "25/09/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/ecalta" }, { "category": "Human", "medicine_affected": "Visudyne", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "verteporfin", "therapeutic_area_mesh": "Myopia, Degenerative;Macular Degeneration", "pharmaceutical_forms_affected": "Powder for solution for infusion", "strengths_affected": "15 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "01/05/2020", "expected_resolution_date": "", "expected_resolution": "Shortages are expected to continue until the end of 2026.", "first_published_date": "08/11/2021", "last_updated_date": "18/09/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/visudyne" }, { "category": "Human", "medicine_affected": "Victoza", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "liraglutide", "therapeutic_area_mesh": "Diabetes Mellitus, Type 2", "pharmaceutical_forms_affected": "Pre-filled pen", "strengths_affected": "6 mg/ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "03/08/2023", "last_updated_date": "05/09/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/victoza" }, { "category": "Human", "medicine_affected": "Zypadhera", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "olanzapine", "therapeutic_area_mesh": "Schizophrenia", "pharmaceutical_forms_affected": "Powder and solvent for prolonged-release suspension for injection", "strengths_affected": "210 mg;300 mg;405 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "October 2025", "first_published_date": "09/07/2024", "last_updated_date": "27/08/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/zypadhera" }, { "category": "Human", "medicine_affected": "Biltricide", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "praziquantel", "therapeutic_area_mesh": "Trematode Infections", "pharmaceutical_forms_affected": "", "strengths_affected": "600 mg film-coated tablets", "availability_of_alternatives": "Yes", "start_of_shortage_date": "26/08/2025", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "26/08/2025", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/biltricide" }, { "category": "Human", "medicine_affected": "Saxenda", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "liraglutide", "therapeutic_area_mesh": "Obesity;Overweight", "pharmaceutical_forms_affected": "Solution for injection in pre-filled pen", "strengths_affected": "6 mg/ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "End of 2025", "first_published_date": "24/08/2023", "last_updated_date": "25/07/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/saxenda" }, { "category": "Human", "medicine_affected": "Amoxicillin and amoxicillin/clavulanic acid", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "amoxicillin;clavulanic acid", "therapeutic_area_mesh": "Bacterial Infections", "pharmaceutical_forms_affected": "Various presentations including paediatric formulations and presentations", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "01/10/2022", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "27/01/2023", "last_updated_date": "17/06/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/amoxicillin-amoxicillin-clavulanic-acid" }, { "category": "Human", "medicine_affected": "NovoSeven (eptacog alfa)", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "eptacog alfa (activated)", "therapeutic_area_mesh": "", "pharmaceutical_forms_affected": "Powder and solvent for solution for injection", "strengths_affected": "1, 2, 5 and 8 mg (50, 100, 250 and 400 KIU)", "availability_of_alternatives": "Unknown", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "December 2025", "first_published_date": "12/05/2025", "last_updated_date": "05/06/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/novoseven-eptacog-alfa" }, { "category": "Human", "medicine_affected": "Pegasys", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "peginterferon alfa-2a", "therapeutic_area_mesh": "Hepatitis C, Chronic;Hepatitis B, Chronic;Polycythemia Vera;Thrombocythemia, Essential", "pharmaceutical_forms_affected": "Solution for injection", "strengths_affected": "90 mcg;135 mcg;180 mcg", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "30/10/2024", "last_updated_date": "05/06/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/pegasys" }, { "category": "Human", "medicine_affected": "Zirabev", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "bevacizumab", "therapeutic_area_mesh": "Colorectal Neoplasms;Breast Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms", "pharmaceutical_forms_affected": "Concentrate for solution for infusion", "strengths_affected": "100mg/4ml ;400mg/16ml", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "17/01/2025", "last_updated_date": "10/04/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/zirabev" }, { "category": "Human", "medicine_affected": "Mimpara", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "cinacalcet", "therapeutic_area_mesh": "Hypercalcemia;Parathyroid Neoplasms;Hyperparathyroidism", "pharmaceutical_forms_affected": "Tablet;Granules in capsule", "strengths_affected": "30, 60, 90mg (tablets);1, 2.5, 5mg (granules in capsule)", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "07/04/2025", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/mimpara" }, { "category": "Human", "medicine_affected": "RoActemra", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "tocilizumab", "therapeutic_area_mesh": "Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;Giant Cell Arteritis;COVID-19 virus infection", "pharmaceutical_forms_affected": "Pre-filled syringe;Pre-filled pen;Solution for subcutaneous injection;Concentrate for solution for infusion", "strengths_affected": "162 mg (syringe, pen) ;20 mg/ml (concentrate)", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "03/09/2021", "last_updated_date": "01/04/2025", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/roactemra" }, { "category": "Human", "medicine_affected": "Fluorouracil", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "fluorouracil", "therapeutic_area_mesh": "Cancer;Neoplasms", "pharmaceutical_forms_affected": "Solution for injection/infusion", "strengths_affected": "", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "2025", "first_published_date": "06/08/2024", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fluorouracil" }, { "category": "Human", "medicine_affected": "Cisplatin", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "cisplatin", "therapeutic_area_mesh": "Cancer;Neoplasms", "pharmaceutical_forms_affected": "Solution for injection", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "06/08/2024", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cisplatin" }, { "category": "Human", "medicine_affected": "Rybelsus", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "semaglutide", "therapeutic_area_mesh": "Diabetes Mellitus, Type 2", "pharmaceutical_forms_affected": "Tablet", "strengths_affected": "3 mg;7 mg;14 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "11/07/2023", "last_updated_date": "22/01/2024", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/rybelsus" }, { "category": "Human", "medicine_affected": "Integrilin", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "eptifibatide", "therapeutic_area_mesh": "Angina, Unstable;Myocardial Infarction", "pharmaceutical_forms_affected": "Solution for injection;Solution for infusion", "strengths_affected": "2 mg/ml (solution for injection);0.75 mg/ml (solution for infusion)", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "17/01/2024", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/integrilin" }, { "category": "Human", "medicine_affected": "Abraxane", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "paclitaxel", "therapeutic_area_mesh": "Breast Neoplasms;Pancreatic Neoplasms;Carcinoma, Non-Small-Cell Lung", "pharmaceutical_forms_affected": "Powder for dispersion for injection", "strengths_affected": "5 mg/ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "11/05/2023", "last_updated_date": "18/12/2023", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/abraxane" }, { "category": "Human", "medicine_affected": "Nulojix", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "belatacept", "therapeutic_area_mesh": "Graft Rejection;Kidney Transplantation", "pharmaceutical_forms_affected": "Solution for infusion", "strengths_affected": "25 mg/ml", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "17/03/2017", "last_updated_date": "03/10/2023", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/nulojix" }, { "category": "Human", "medicine_affected": "Kevzara", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "sarilumab", "therapeutic_area_mesh": "Arthritis, Rheumatoid", "pharmaceutical_forms_affected": "Pre-filled syringe;Pre-filled pen;Solution for subcutaneous injection", "strengths_affected": "150 mg;200 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "09/11/2021", "last_updated_date": "14/09/2023", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/kevzara" }, { "category": "Human", "medicine_affected": "Insuman Rapid, Basal and Comb 25 (insulin human)", "supply_shortage_status": "Ongoing", "international_non_proprietary_name_inn_or_common_name": "insulin human", "therapeutic_area_mesh": "Diabetes Mellitus", "pharmaceutical_forms_affected": "Solution for injection;Pre-filled pen", "strengths_affected": "3 ml", "availability_of_alternatives": "", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "24/01/2023", "last_updated_date": "19/07/2023", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insuman-rapid-basal-comb-25-insulin-human" }, { "category": "Human", "medicine_affected": "Actilyse and Actilyse Cathflo", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "alteplase", "therapeutic_area_mesh": "Myocardial Infarction", "pharmaceutical_forms_affected": "Powder and solvent for solution for injection/infusion", "strengths_affected": "10 mg (Actilyse);20 mg (Actilyse);50 mg (Actilyse);2 mg (Actilyse Cathflo)", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "23/09/2022", "last_updated_date": "11/05/2023", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/actilyse-actilyse-cathflo" }, { "category": "Human", "medicine_affected": "Metalyse", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "tenecteplase", "therapeutic_area_mesh": "Myocardial Infarction", "pharmaceutical_forms_affected": "Powder and solvent for solution for injection", "strengths_affected": "8,000 units (40 mg);10,000 units (50 mg)", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "23/09/2022", "last_updated_date": "11/05/2023", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/metalyse" }, { "category": "Human", "medicine_affected": "Zerbaxa", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "ceftolozane;tazobactam", "therapeutic_area_mesh": "Bacterial Infections", "pharmaceutical_forms_affected": "Concentrate for solution for infusion", "strengths_affected": "1 g;0.5 g", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "22/12/2020", "last_updated_date": "14/04/2023", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/zerbaxa" }, { "category": "Human", "medicine_affected": "Cetrotide", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "cetrorelix acetate", "therapeutic_area_mesh": "Ovulation;Ovulation Induction", "pharmaceutical_forms_affected": "Powder and solvent for solution for infusion", "strengths_affected": "0.25 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "10/08/2022", "last_updated_date": "15/02/2023", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cetrotide" }, { "category": "Human", "medicine_affected": "Orgalutran", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "ganirelix", "therapeutic_area_mesh": "Reproductive Techniques, Assisted;Ovulation Induction;Infertility, Female", "pharmaceutical_forms_affected": "Solution for injection in pre-filled pen", "strengths_affected": "0.25 mg/0.5 ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "16/02/2017", "last_updated_date": "08/11/2022", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/orgalutran" }, { "category": "Human", "medicine_affected": "Vfend", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "voriconazole", "therapeutic_area_mesh": "Candidiasis;Mycoses;Aspergillosis", "pharmaceutical_forms_affected": "Powder for solution for infusion", "strengths_affected": "200 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "16/04/2021", "last_updated_date": "30/06/2021", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/vfend" }, { "category": "Human", "medicine_affected": "Respreeza", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "alpha1-proteinase inhibitor (human)", "therapeutic_area_mesh": "Genetic Diseases, Inborn;Lung Diseases", "pharmaceutical_forms_affected": "Powder and solvent for solution for infusion", "strengths_affected": "4,000 mg ;5,000 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "06/04/2021", "last_updated_date": "06/05/2021", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/respreeza-0" }, { "category": "Human", "medicine_affected": "Respreeza", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "alpha1-proteinase inhibitor (human)", "therapeutic_area_mesh": "Genetic Diseases, Inborn;Lung Diseases", "pharmaceutical_forms_affected": "Powder and solvent for solution for infusion", "strengths_affected": "1,000 mg ;4,000 mg ;5,000 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "25/02/2021", "last_updated_date": "31/03/2021", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/respreeza" }, { "category": "Human", "medicine_affected": "Nucala", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "mepolizumab", "therapeutic_area_mesh": "Asthma", "pharmaceutical_forms_affected": "Pre-filled pen", "strengths_affected": "40 mg ;100 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "28/01/2021", "last_updated_date": "01/03/2021", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/nucala" }, { "category": "Human", "medicine_affected": "Cinryze", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "C1 inhibitor (human)", "therapeutic_area_mesh": "Angioedemas, Hereditary", "pharmaceutical_forms_affected": "Powder and solvent for intravenous injection", "strengths_affected": "500 IU", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "06/08/2018", "last_updated_date": "25/06/2020", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cinryze" }, { "category": "Human", "medicine_affected": "Tygacil", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "tigecycline", "therapeutic_area_mesh": "Bacterial Infections;Skin Diseases, Bacterial;Soft Tissue Infections", "pharmaceutical_forms_affected": "Powder for solution for infusion", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "22/05/2015", "last_updated_date": "07/11/2019", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/tygacil" }, { "category": "Human", "medicine_affected": "Cerezyme", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "imiglucerase", "therapeutic_area_mesh": "Gaucher Disease", "pharmaceutical_forms_affected": "Solution for infusion", "strengths_affected": "", "availability_of_alternatives": "No", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "04/11/2013", "last_updated_date": "01/10/2018", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/cerezyme" }, { "category": "Human", "medicine_affected": "Trisenox", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "arsenic trioxide", "therapeutic_area_mesh": "Leukemia, Promyelocytic, Acute", "pharmaceutical_forms_affected": "Solution for infusion", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "31/07/2017", "last_updated_date": "06/09/2018", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/trisenox" }, { "category": "Human", "medicine_affected": "Arixtra", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "fondaparinux sodium", "therapeutic_area_mesh": "Venous Thrombosis;Pulmonary Embolism;Myocardial Infarction;Angina, Unstable", "pharmaceutical_forms_affected": "Pre-filled syringe", "strengths_affected": "1.5 mg;2.5 mg;5.0 mg;7.5 mg", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "07/07/2017", "last_updated_date": "21/03/2018", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/arixtra" }, { "category": "Human", "medicine_affected": "Inductos", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "dibotermin alfa", "therapeutic_area_mesh": "Tibial Fractures;Fracture Fixation, Internal;Spinal Fusion", "pharmaceutical_forms_affected": "Powder, solvent and matrix for implantation matrix", "strengths_affected": "", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "16/09/2015", "last_updated_date": "15/08/2017", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/inductos" }, { "category": "Human", "medicine_affected": "Insuman Basal and Comb 25", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "insulin human", "therapeutic_area_mesh": "Diabetes Mellitus", "pharmaceutical_forms_affected": "Catridge;Pre-filled pen", "strengths_affected": "3 ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "01/12/2015", "last_updated_date": "18/11/2016", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insuman-basal-comb-25" }, { "category": "Human", "medicine_affected": "Taxotere", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "docetaxel", "therapeutic_area_mesh": "Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Stomach Neoplasms;Breast Neoplasms", "pharmaceutical_forms_affected": "Concentrate for solution for infusion", "strengths_affected": "20 mg;1 ml and 80g;4 ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "19/05/2016", "last_updated_date": "19/09/2016", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/taxotere" }, { "category": "Human", "medicine_affected": "Fabrazyme", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "agalsidase beta", "therapeutic_area_mesh": "Fabry Disease", "pharmaceutical_forms_affected": "Powder for concentrate for solution for infusion", "strengths_affected": "5 mg;35 mg", "availability_of_alternatives": "No", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "04/11/2013", "last_updated_date": "07/06/2016", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/fabrazyme" }, { "category": "Human", "medicine_affected": "Insuman Rapid, Basal and Comb", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "insulin human", "therapeutic_area_mesh": "Diabetes Mellitus", "pharmaceutical_forms_affected": "Catridge;Pre-filled pen", "strengths_affected": "3 ml", "availability_of_alternatives": "Yes", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "31/03/2015", "last_updated_date": "25/09/2015", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/insuman-rapid-basal-comb" }, { "category": "Human", "medicine_affected": "Xofigo", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "radium Ra223 dichloride", "therapeutic_area_mesh": "Prostatic Neoplasms", "pharmaceutical_forms_affected": "Solution for injection", "strengths_affected": "1100 kBq/ml", "availability_of_alternatives": "No", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "17/10/2014", "last_updated_date": "30/04/2015", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/xofigo" }, { "category": "Human", "medicine_affected": "Buccolam", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "midazolam", "therapeutic_area_mesh": "Epilepsy", "pharmaceutical_forms_affected": "Pre-filled syringe", "strengths_affected": "2.5 mg;5 mg;7.5 mg;10 mg", "availability_of_alternatives": "Not stated", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "25/04/2014", "last_updated_date": "30/03/2015", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/buccolam" }, { "category": "Human", "medicine_affected": "Enbrel", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "etanercept", "therapeutic_area_mesh": "Spondylitis, Ankylosing;Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Psoriasis;Arthritis, Rheumatoid", "pharmaceutical_forms_affected": "Pre-filled syringe;Pre-filled pen", "strengths_affected": "10 mg;25 mg;50 mg", "availability_of_alternatives": "No", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "19/02/2014", "last_updated_date": "07/05/2014", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/enbrel" }, { "category": "Human", "medicine_affected": "Increlex", "supply_shortage_status": "Resolved", "international_non_proprietary_name_inn_or_common_name": "mecasermin", "therapeutic_area_mesh": "Laron Syndrome", "pharmaceutical_forms_affected": "Solution for subcutaneous injection", "strengths_affected": "10 mg/ml", "availability_of_alternatives": "No", "start_of_shortage_date": "", "expected_resolution_date": "", "expected_resolution": "", "first_published_date": "20/12/2013", "last_updated_date": "", "shortage_url": "https://www.ema.europa.eu/en/medicines/human/shortages/increlex" } ] }